US Patent Issued to AstraZeneca UK, Daiichi Sankyo on Sept. 1 for "Combination of anti-HER2 antibody-drug conjugate and PARP1 selective inhibitor" (British, American Inventors)

ALEXANDRIA, Va., Sept. 1 -- United States Patent no. 12,721,905, issued on Sept. 1, was assigned to AstraZeneca UK Ltd. (Cambridge, Great Britain) and Daiichi Sankyo Co. Ltd. (Tokyo).

"Combination of anti-HER2 antibody-drug conjugate and PARP1 selective inhibitor" was invented by Jerome Thomas Mettetal II (Wilmington, Del.), Azadeh Cheraghchi Bashi Astaneh (Cambridge, Great Britain), Elisabetta Leo (Cambridge, Great Britain) and Yann Wallez (Cambridge, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "A pharmaceutical product for administration of an anti-HER2 antibody-drug conjugate in combination with a PARP1 selective inhibitor is provided. The anti-HER2 antibody drug conjugate is an antibody-d...